Trabectedin  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
treatment  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
relapsed  ||| S:33 E:42 ||| JJ
ovarian  ||| S:42 E:50 ||| JJ
cancer  ||| S:50 E:57 ||| NN
The  ||| S:57 E:61 ||| DT
paper  ||| S:61 E:67 ||| NN
presents  ||| S:67 E:76 ||| VBZ
a  ||| S:76 E:78 ||| DT
summary  ||| S:78 E:86 ||| NN
of  ||| S:86 E:89 ||| IN
the  ||| S:89 E:93 ||| DT
evidence  ||| S:93 E:102 ||| NN
review  ||| S:102 E:109 ||| NN
group  ||| S:109 E:115 ||| NN
( ||| S:115 E:116 ||| -LRB-
ERG ||| S:116 E:119 ||| NNP
)  ||| S:119 E:121 ||| -RRB-
report  ||| S:121 E:128 ||| NN
into  ||| S:128 E:133 ||| IN
the  ||| S:133 E:137 ||| DT
clinical  ||| S:137 E:146 ||| JJ
effectiveness  ||| S:146 E:160 ||| NN
and  ||| S:160 E:164 ||| CC
cost-effectiveness  ||| S:164 E:183 ||| JJ
of  ||| S:183 E:186 ||| IN
trabectedin  ||| S:186 E:198 ||| NN
for  ||| S:198 E:202 ||| IN
the  ||| S:202 E:206 ||| DT
treatment  ||| S:206 E:216 ||| NN
of  ||| S:216 E:219 ||| IN
relapsed  ||| S:219 E:228 ||| JJ
platinum-sensitive  ||| S:228 E:247 ||| JJ
ovarian  ||| S:247 E:255 ||| JJ
cancer ||| S:255 E:261 ||| NN
,  ||| S:261 E:263 ||| ,
based  ||| S:263 E:269 ||| VBN
upon  ||| S:269 E:274 ||| IN
a  ||| S:274 E:276 ||| DT
review  ||| S:276 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
the  ||| S:286 E:290 ||| DT
manufacturer ||| S:290 E:302 ||| NN
's  ||| S:302 E:305 ||| POS
submission  ||| S:305 E:316 ||| NN
to  ||| S:316 E:319 ||| TO
the  ||| S:319 E:323 ||| DT
National  ||| S:323 E:332 ||| NNP
Institute  ||| S:332 E:342 ||| NNP
for  ||| S:342 E:346 ||| IN
Health  ||| S:346 E:353 ||| NNP
and  ||| S:353 E:357 ||| CC
Clinical  ||| S:357 E:366 ||| NNP
Excellence  ||| S:366 E:377 ||| NNP
( ||| S:377 E:378 ||| -LRB-
NICE ||| S:378 E:382 ||| NNP
)  ||| S:382 E:384 ||| -RRB-
as  ||| S:384 E:387 ||| IN
part  ||| S:387 E:392 ||| NN
of  ||| S:392 E:395 ||| IN
the  ||| S:395 E:399 ||| DT
single  ||| S:399 E:406 ||| JJ
technology  ||| S:406 E:417 ||| NN
appraisal  ||| S:417 E:427 ||| NN
process ||| S:427 E:434 ||| NN
.  ||| S:434 E:436 ||| .
The  ||| S:436 E:440 ||| DT
submission  ||| S:440 E:451 ||| NN
addressed  ||| S:451 E:461 ||| VBD
only  ||| S:461 E:466 ||| JJ
part  ||| S:466 E:471 ||| NN
of  ||| S:471 E:474 ||| IN
the  ||| S:474 E:478 ||| DT
decision  ||| S:478 E:487 ||| NN
problem  ||| S:487 E:495 ||| NN
and  ||| S:495 E:499 ||| CC
did  ||| S:499 E:503 ||| VBD
not  ||| S:503 E:507 ||| RB
provide  ||| S:507 E:515 ||| VB
evidence  ||| S:515 E:524 ||| NN
to  ||| S:524 E:527 ||| TO
compare  ||| S:527 E:535 ||| VB
trabectedin  ||| S:535 E:547 ||| NNS
( ||| S:547 E:548 ||| -LRB-
Yondelis® ||| S:548 E:557 ||| NNP
,  ||| S:557 E:559 ||| ,
PharmaMar ||| S:559 E:568 ||| NNP
)  ||| S:568 E:570 ||| -RRB-
and  ||| S:570 E:574 ||| CC
pegylated  ||| S:574 E:584 ||| FW
liposomal  ||| S:584 E:594 ||| FW
doxorubicin  ||| S:594 E:606 ||| FW
hydrochloride  ||| S:606 E:620 ||| FW
( ||| S:620 E:621 ||| -LRB-
PLDH ||| S:621 E:625 ||| NNP
)  ||| S:625 E:627 ||| -RRB-
( ||| S:627 E:628 ||| -LRB-
Caelyx® ||| S:628 E:635 ||| NNP
,  ||| S:635 E:637 ||| ,
Schering-Plough ||| S:637 E:652 ||| NNP
)  ||| S:652 E:654 ||| -RRB-
with  ||| S:654 E:659 ||| IN
key  ||| S:659 E:663 ||| JJ
comparators ||| S:663 E:674 ||| NN
.  ||| S:674 E:676 ||| .
The  ||| S:676 E:680 ||| DT
submission ||| S:680 E:690 ||| NN
's  ||| S:690 E:693 ||| POS
direct  ||| S:693 E:700 ||| JJ
comparison  ||| S:700 E:711 ||| NN
evidence  ||| S:711 E:720 ||| NN
came  ||| S:720 E:725 ||| VBD
from  ||| S:725 E:730 ||| IN
one  ||| S:730 E:734 ||| CD
reasonable-quality  ||| S:734 E:753 ||| JJ
randomised  ||| S:753 E:764 ||| NNS
controlled  ||| S:764 E:775 ||| VBN
trial  ||| S:775 E:781 ||| NN
( ||| S:781 E:782 ||| -LRB-
RCT ||| S:782 E:785 ||| NNP
)  ||| S:785 E:787 ||| -RRB-
of  ||| S:787 E:790 ||| IN
trabectedin  ||| S:790 E:802 ||| NN
and  ||| S:802 E:806 ||| CC
PLDH  ||| S:806 E:811 ||| NNP
versus  ||| S:811 E:818 ||| FW
PLDH  ||| S:818 E:823 ||| FW
alone  ||| S:823 E:829 ||| FW
( ||| S:829 E:830 ||| -LRB-
ET743-OVA-301 ||| S:830 E:843 ||| NNP
) ||| S:843 E:844 ||| -RRB-
.  ||| S:844 E:846 ||| .
The  ||| S:846 E:850 ||| DT
results  ||| S:850 E:858 ||| NNS
of  ||| S:858 E:861 ||| IN
the  ||| S:861 E:865 ||| DT
RCT  ||| S:865 E:869 ||| NNP
were  ||| S:869 E:874 ||| VBD
subdivided  ||| S:874 E:885 ||| VBN
into  ||| S:885 E:890 ||| IN
the  ||| S:890 E:894 ||| DT
entire  ||| S:894 E:901 ||| JJ
platinum-sensitive  ||| S:901 E:920 ||| JJ
population  ||| S:920 E:931 ||| NN
( ||| S:931 E:932 ||| -LRB-
>  ||| S:932 E:934 ||| CD
6-month  ||| S:934 E:942 ||| CD
relapse  ||| S:942 E:950 ||| NN
after  ||| S:950 E:956 ||| IN
initial  ||| S:956 E:964 ||| JJ
platinum-based  ||| S:964 E:979 ||| JJ
chemotherapy ||| S:979 E:991 ||| NN
)  ||| S:991 E:993 ||| -RRB-
and  ||| S:993 E:997 ||| CC
partially  ||| S:997 E:1007 ||| RB
platinum-sensitive  ||| S:1007 E:1026 ||| JJ
( ||| S:1026 E:1027 ||| -LRB-
≥  ||| S:1027 E:1029 ||| CD
6-  ||| S:1029 E:1032 ||| CD
to  ||| S:1032 E:1035 ||| TO
12-month  ||| S:1035 E:1044 ||| JJ
relapse ||| S:1044 E:1051 ||| NN
)  ||| S:1051 E:1053 ||| -RRB-
and  ||| S:1053 E:1057 ||| CC
fully  ||| S:1057 E:1063 ||| RB
platinum-sensitive  ||| S:1063 E:1082 ||| JJ
( ||| S:1082 E:1083 ||| -LRB-
>  ||| S:1083 E:1085 ||| CD
12-month  ||| S:1085 E:1094 ||| JJ
relapse ||| S:1094 E:1101 ||| NN
)  ||| S:1101 E:1103 ||| -RRB-
populations ||| S:1103 E:1114 ||| NNS
.  ||| S:1114 E:1116 ||| .
The  ||| S:1116 E:1120 ||| DT
outcomes  ||| S:1120 E:1129 ||| NN
included  ||| S:1129 E:1138 ||| VBD
were  ||| S:1138 E:1143 ||| VBD
overall  ||| S:1143 E:1151 ||| JJ
survival ||| S:1151 E:1159 ||| NN
,  ||| S:1159 E:1161 ||| ,
progression-free  ||| S:1161 E:1178 ||| JJ
survival  ||| S:1178 E:1187 ||| NN
measured  ||| S:1187 E:1196 ||| VBN
by  ||| S:1196 E:1199 ||| IN
three  ||| S:1199 E:1205 ||| CD
types  ||| S:1205 E:1211 ||| NNS
of  ||| S:1211 E:1214 ||| IN
assessor ||| S:1214 E:1222 ||| NN
,  ||| S:1222 E:1224 ||| ,
response  ||| S:1224 E:1233 ||| NN
rates ||| S:1233 E:1238 ||| NNS
,  ||| S:1238 E:1240 ||| ,
adverse  ||| S:1240 E:1248 ||| JJ
effects  ||| S:1248 E:1256 ||| NNS
of  ||| S:1256 E:1259 ||| IN
treatment ||| S:1259 E:1268 ||| NN
,  ||| S:1268 E:1270 ||| ,
health-related  ||| S:1270 E:1285 ||| JJ
quality  ||| S:1285 E:1293 ||| NN
of  ||| S:1293 E:1296 ||| IN
life  ||| S:1296 E:1301 ||| NN
and  ||| S:1301 E:1305 ||| CC
cost  ||| S:1305 E:1310 ||| NN
per  ||| S:1310 E:1314 ||| IN
quality-adjusted-life-year  ||| S:1314 E:1341 ||| NNP
( ||| S:1341 E:1342 ||| -LRB-
QALY ||| S:1342 E:1346 ||| NNP
)  ||| S:1346 E:1348 ||| -RRB-
gained ||| S:1348 E:1354 ||| VBD
.  ||| S:1354 E:1356 ||| .
A  ||| S:1356 E:1358 ||| DT
mixed  ||| S:1358 E:1364 ||| JJ
treatment  ||| S:1364 E:1374 ||| NN
comparison  ||| S:1374 E:1385 ||| NN
( ||| S:1385 E:1386 ||| -LRB-
MTC ||| S:1386 E:1389 ||| NNP
)  ||| S:1389 E:1391 ||| -RRB-
meta-analysis  ||| S:1391 E:1405 ||| JJ
comparing  ||| S:1405 E:1415 ||| JJ
trabectedin  ||| S:1415 E:1427 ||| NN
and  ||| S:1427 E:1431 ||| CC
PLDH  ||| S:1431 E:1436 ||| NNP
with  ||| S:1436 E:1441 ||| IN
single-agent  ||| S:1441 E:1454 ||| JJ
PLDH  ||| S:1454 E:1459 ||| NN
within  ||| S:1459 E:1466 ||| IN
the  ||| S:1466 E:1470 ||| DT
entire  ||| S:1470 E:1477 ||| JJ
platinum-sensitive  ||| S:1477 E:1496 ||| JJ
population ||| S:1496 E:1506 ||| NN
,  ||| S:1506 E:1508 ||| ,
with  ||| S:1508 E:1513 ||| IN
paclitaxel  ||| S:1513 E:1524 ||| NN
or  ||| S:1524 E:1527 ||| CC
with  ||| S:1527 E:1532 ||| IN
topotecan  ||| S:1532 E:1542 ||| VBG
also  ||| S:1542 E:1547 ||| RB
formed  ||| S:1547 E:1554 ||| VBN
part  ||| S:1554 E:1559 ||| NN
of  ||| S:1559 E:1562 ||| IN
the  ||| S:1562 E:1566 ||| DT
submission ||| S:1566 E:1576 ||| NN
.  ||| S:1576 E:1578 ||| .
The  ||| S:1578 E:1582 ||| DT
RCT  ||| S:1582 E:1586 ||| NNP
data  ||| S:1586 E:1591 ||| NNS
showed  ||| S:1591 E:1598 ||| VBD
that  ||| S:1598 E:1603 ||| DT
trabectedin  ||| S:1603 E:1615 ||| NN
plus  ||| S:1615 E:1620 ||| CC
PLDH  ||| S:1620 E:1625 ||| NNP
compared  ||| S:1625 E:1634 ||| VBN
with  ||| S:1634 E:1639 ||| IN
PLDH  ||| S:1639 E:1644 ||| NNP
monotherapy  ||| S:1644 E:1656 ||| NN
had  ||| S:1656 E:1660 ||| VBD
a  ||| S:1660 E:1662 ||| DT
significant  ||| S:1662 E:1674 ||| JJ
effect  ||| S:1674 E:1681 ||| NN
on  ||| S:1681 E:1684 ||| IN
overall  ||| S:1684 E:1692 ||| JJ
survival  ||| S:1692 E:1701 ||| NN
only  ||| S:1701 E:1706 ||| RB
within  ||| S:1706 E:1713 ||| IN
the  ||| S:1713 E:1717 ||| DT
partially  ||| S:1717 E:1727 ||| RB
platinum-sensitive  ||| S:1727 E:1746 ||| JJ
subgroup ||| S:1746 E:1754 ||| NN
.  ||| S:1754 E:1756 ||| .
PFS  ||| S:1756 E:1760 ||| NNP
results  ||| S:1760 E:1768 ||| NNS
reported  ||| S:1768 E:1777 ||| VBD
by  ||| S:1777 E:1780 ||| IN
the  ||| S:1780 E:1784 ||| DT
independent  ||| S:1784 E:1796 ||| JJ
radiologists  ||| S:1796 E:1809 ||| NN
showed  ||| S:1809 E:1816 ||| VBD
significant  ||| S:1816 E:1828 ||| JJ
effects  ||| S:1828 E:1836 ||| NNS
in  ||| S:1836 E:1839 ||| IN
favour  ||| S:1839 E:1846 ||| NN
of  ||| S:1846 E:1849 ||| IN
the  ||| S:1849 E:1853 ||| DT
trabectedin  ||| S:1853 E:1865 ||| NN
and  ||| S:1865 E:1869 ||| CC
PLDH  ||| S:1869 E:1874 ||| NNP
arm  ||| S:1874 E:1878 ||| NN
for  ||| S:1878 E:1882 ||| IN
the  ||| S:1882 E:1886 ||| DT
entire  ||| S:1886 E:1893 ||| JJ
and  ||| S:1893 E:1897 ||| CC
partially  ||| S:1897 E:1907 ||| RB
platinum-sensitive  ||| S:1907 E:1926 ||| JJ
populations  ||| S:1926 E:1938 ||| NNS
only ||| S:1938 E:1942 ||| RB
.  ||| S:1942 E:1944 ||| .
Rates  ||| S:1944 E:1950 ||| NNS
of  ||| S:1950 E:1953 ||| IN
grade  ||| S:1953 E:1959 ||| CD
3  ||| S:1959 E:1961 ||| CD
and  ||| S:1961 E:1965 ||| CC
4  ||| S:1965 E:1967 ||| CD
adverse  ||| S:1967 E:1975 ||| JJ
events  ||| S:1975 E:1982 ||| NNS
were  ||| S:1982 E:1987 ||| VBD
mostly  ||| S:1987 E:1994 ||| RB
higher  ||| S:1994 E:2001 ||| JJR
in  ||| S:2001 E:2004 ||| IN
the  ||| S:2004 E:2008 ||| DT
trabectedin  ||| S:2008 E:2020 ||| NN
and  ||| S:2020 E:2024 ||| CC
PLDH  ||| S:2024 E:2029 ||| NNP
arm  ||| S:2029 E:2033 ||| NN
than  ||| S:2033 E:2038 ||| IN
in  ||| S:2038 E:2041 ||| IN
the  ||| S:2041 E:2045 ||| DT
PLDH  ||| S:2045 E:2050 ||| NNP
alone  ||| S:2050 E:2056 ||| JJ
arm ||| S:2056 E:2059 ||| NN
.  ||| S:2059 E:2061 ||| .
There  ||| S:2061 E:2067 ||| EX
were  ||| S:2067 E:2072 ||| VBD
several  ||| S:2072 E:2080 ||| JJ
issues  ||| S:2080 E:2087 ||| NNS
regarding  ||| S:2087 E:2097 ||| VBG
the  ||| S:2097 E:2101 ||| DT
undertaking  ||| S:2101 E:2113 ||| NN
of  ||| S:2113 E:2116 ||| IN
the  ||| S:2116 E:2120 ||| DT
MTC ||| S:2120 E:2123 ||| NNP
,  ||| S:2123 E:2125 ||| ,
and  ||| S:2125 E:2129 ||| CC
thus  ||| S:2129 E:2134 ||| RB
the  ||| S:2134 E:2138 ||| DT
data  ||| S:2138 E:2143 ||| NNS
were  ||| S:2143 E:2148 ||| VBD
not  ||| S:2148 E:2152 ||| RB
considered  ||| S:2152 E:2163 ||| VBN
robust ||| S:2163 E:2169 ||| JJ
.  ||| S:2169 E:2171 ||| .
Furthermore ||| S:2171 E:2182 ||| RB
,  ||| S:2182 E:2184 ||| ,
the  ||| S:2184 E:2188 ||| DT
ERG  ||| S:2188 E:2192 ||| NNP
did  ||| S:2192 E:2196 ||| VBD
not  ||| S:2196 E:2200 ||| RB
believe  ||| S:2200 E:2208 ||| VB
the  ||| S:2208 E:2212 ||| DT
MTC  ||| S:2212 E:2216 ||| NNP
to  ||| S:2216 E:2219 ||| TO
be  ||| S:2219 E:2222 ||| VB
necessary  ||| S:2222 E:2232 ||| JJ
to  ||| S:2232 E:2235 ||| TO
answer  ||| S:2235 E:2242 ||| VB
the  ||| S:2242 E:2246 ||| DT
decision  ||| S:2246 E:2255 ||| NN
problem ||| S:2255 E:2262 ||| NN
.  ||| S:2262 E:2264 ||| .
The  ||| S:2264 E:2268 ||| DT
manufacturer  ||| S:2268 E:2281 ||| NN
submitted  ||| S:2281 E:2291 ||| VBD
a  ||| S:2291 E:2293 ||| DT
de  ||| S:2293 E:2296 ||| FW
novo  ||| S:2296 E:2301 ||| FW
cost-effectiveness  ||| S:2301 E:2320 ||| JJ
model ||| S:2320 E:2325 ||| NN
.  ||| S:2325 E:2327 ||| .
The  ||| S:2327 E:2331 ||| DT
main  ||| S:2331 E:2336 ||| JJ
analysis  ||| S:2336 E:2345 ||| NN
compared  ||| S:2345 E:2354 ||| VBN
trabectedin  ||| S:2354 E:2366 ||| VBN
in  ||| S:2366 E:2369 ||| IN
combination  ||| S:2369 E:2381 ||| NN
with  ||| S:2381 E:2386 ||| IN
PLDH  ||| S:2386 E:2391 ||| NNP
versus  ||| S:2391 E:2398 ||| FW
paclitaxel ||| S:2398 E:2408 ||| FW
,  ||| S:2408 E:2410 ||| ,
topotecan  ||| S:2410 E:2420 ||| NN
and  ||| S:2420 E:2424 ||| CC
PLDH  ||| S:2424 E:2429 ||| NNP
( ||| S:2429 E:2430 ||| -LRB-
each  ||| S:2430 E:2435 ||| DT
as  ||| S:2435 E:2438 ||| IN
monotherapy ||| S:2438 E:2449 ||| CD
)  ||| S:2449 E:2451 ||| -RRB-
in  ||| S:2451 E:2454 ||| IN
the  ||| S:2454 E:2458 ||| DT
entire  ||| S:2458 E:2465 ||| JJ
platinum-sensitive  ||| S:2465 E:2484 ||| JJ
population ||| S:2484 E:2494 ||| NN
,  ||| S:2494 E:2496 ||| ,
using  ||| S:2496 E:2502 ||| VBG
results  ||| S:2502 E:2510 ||| NNS
estimated  ||| S:2510 E:2520 ||| VBN
from  ||| S:2520 E:2525 ||| IN
the  ||| S:2525 E:2529 ||| DT
MTC ||| S:2529 E:2532 ||| NNP
.  ||| S:2532 E:2534 ||| .
Additional  ||| S:2534 E:2545 ||| JJ
analyses  ||| S:2545 E:2554 ||| NNS
were  ||| S:2554 E:2559 ||| VBD
presented  ||| S:2559 E:2569 ||| VBN
comparing  ||| S:2569 E:2579 ||| VBG
trabectedin  ||| S:2579 E:2591 ||| NN
in  ||| S:2591 E:2594 ||| IN
combination  ||| S:2594 E:2606 ||| NN
with  ||| S:2606 E:2611 ||| IN
PLDH  ||| S:2611 E:2616 ||| NNP
versus  ||| S:2616 E:2623 ||| CC
PLDH  ||| S:2623 E:2628 ||| NNP
monotherapy  ||| S:2628 E:2640 ||| VBZ
using  ||| S:2640 E:2646 ||| VBG
direct  ||| S:2646 E:2653 ||| JJ
evidence  ||| S:2653 E:2662 ||| NN
from  ||| S:2662 E:2667 ||| IN
the  ||| S:2667 E:2671 ||| DT
OVA-301  ||| S:2671 E:2679 ||| JJ
trial  ||| S:2679 E:2685 ||| NN
for  ||| S:2685 E:2689 ||| IN
the  ||| S:2689 E:2693 ||| DT
fully ||| S:2693 E:2698 ||| RB
,  ||| S:2698 E:2700 ||| ,
partially  ||| S:2700 E:2710 ||| RB
and  ||| S:2710 E:2714 ||| CC
entire  ||| S:2714 E:2721 ||| JJ
platinum-sensitive  ||| S:2721 E:2740 ||| JJ
populations ||| S:2740 E:2751 ||| NNS
.  ||| S:2751 E:2753 ||| .
The  ||| S:2753 E:2757 ||| DT
cost  ||| S:2757 E:2762 ||| NN
per  ||| S:2762 E:2766 ||| IN
QALY  ||| S:2766 E:2771 ||| NNP
gained  ||| S:2771 E:2778 ||| VBD
for  ||| S:2778 E:2782 ||| IN
trabectedin  ||| S:2782 E:2794 ||| NN
in  ||| S:2794 E:2797 ||| IN
combination  ||| S:2797 E:2809 ||| NN
with  ||| S:2809 E:2814 ||| IN
PLDH  ||| S:2814 E:2819 ||| NNP
versus  ||| S:2819 E:2826 ||| CC
PLDH  ||| S:2826 E:2831 ||| NNP
monotherapy  ||| S:2831 E:2843 ||| NN
was  ||| S:2843 E:2847 ||| VBD
estimated  ||| S:2847 E:2857 ||| VBN
to  ||| S:2857 E:2860 ||| TO
be  ||| S:2860 E:2863 ||| VB
£  ||| S:2863 E:2865 ||| CD
70,076  ||| S:2865 E:2872 ||| CD
in  ||| S:2872 E:2875 ||| IN
the  ||| S:2875 E:2879 ||| DT
main  ||| S:2879 E:2884 ||| JJ
analysis ||| S:2884 E:2892 ||| NN
.  ||| S:2892 E:2894 ||| .
In  ||| S:2894 E:2897 ||| IN
the  ||| S:2897 E:2901 ||| DT
additional  ||| S:2901 E:2912 ||| JJ
analyses ||| S:2912 E:2920 ||| NNS
,  ||| S:2920 E:2922 ||| ,
the  ||| S:2922 E:2926 ||| DT
cost  ||| S:2926 E:2931 ||| NN
per  ||| S:2931 E:2935 ||| IN
QALY  ||| S:2935 E:2940 ||| NNP
gained  ||| S:2940 E:2947 ||| VBD
for  ||| S:2947 E:2951 ||| IN
trabectedin  ||| S:2951 E:2963 ||| NN
in  ||| S:2963 E:2966 ||| IN
combination  ||| S:2966 E:2978 ||| NN
with  ||| S:2978 E:2983 ||| IN
PLDH  ||| S:2983 E:2988 ||| NNP
versus  ||| S:2988 E:2995 ||| CC
PLDH  ||| S:2995 E:3000 ||| NNP
monotherapy  ||| S:3000 E:3012 ||| NN
was  ||| S:3012 E:3016 ||| VBD
£  ||| S:3016 E:3018 ||| CD
94,832 ||| S:3018 E:3024 ||| CD
,  ||| S:3024 E:3026 ||| ,
£  ||| S:3026 E:3028 ||| NNP
43,996  ||| S:3028 E:3035 ||| NNP
and  ||| S:3035 E:3039 ||| CC
£  ||| S:3039 E:3041 ||| CD
31,092  ||| S:3041 E:3048 ||| CD
for  ||| S:3048 E:3052 ||| IN
the  ||| S:3052 E:3056 ||| DT
entire ||| S:3056 E:3062 ||| JJ
,  ||| S:3062 E:3064 ||| ,
partially  ||| S:3064 E:3074 ||| RB
and  ||| S:3074 E:3078 ||| CC
fully  ||| S:3078 E:3084 ||| RB
platinum-sensitive  ||| S:3084 E:3103 ||| JJ
populations ||| S:3103 E:3114 ||| NNS
,  ||| S:3114 E:3116 ||| ,
respectively ||| S:3116 E:3128 ||| RB
.  ||| S:3128 E:3130 ||| .
Additional  ||| S:3130 E:3141 ||| JJ
work  ||| S:3141 E:3146 ||| NN
was  ||| S:3146 E:3150 ||| VBD
undertaken  ||| S:3150 E:3161 ||| VBN
by  ||| S:3161 E:3164 ||| IN
the  ||| S:3164 E:3168 ||| DT
ERG  ||| S:3168 E:3172 ||| NNP
using  ||| S:3172 E:3178 ||| VBG
patient-level  ||| S:3178 E:3192 ||| JJ
data  ||| S:3192 E:3197 ||| NNS
and  ||| S:3197 E:3201 ||| CC
amending  ||| S:3201 E:3210 ||| VBG
some  ||| S:3210 E:3215 ||| DT
assumptions  ||| S:3215 E:3227 ||| NNS
to  ||| S:3227 E:3230 ||| TO
provide  ||| S:3230 E:3238 ||| VB
a  ||| S:3238 E:3240 ||| DT
better  ||| S:3240 E:3247 ||| RBR
statistical  ||| S:3247 E:3259 ||| JJ
fit  ||| S:3259 E:3263 ||| NN
to  ||| S:3263 E:3266 ||| TO
the  ||| S:3266 E:3270 ||| DT
Kaplan-Meier  ||| S:3270 E:3283 ||| JJ
data  ||| S:3283 E:3288 ||| NNS
than  ||| S:3288 E:3293 ||| IN
the  ||| S:3293 E:3297 ||| DT
exponential  ||| S:3297 E:3309 ||| JJ
distribution  ||| S:3309 E:3322 ||| NN
assumed  ||| S:3322 E:3330 ||| VBD
by  ||| S:3330 E:3333 ||| IN
the  ||| S:3333 E:3337 ||| DT
manufacturer ||| S:3337 E:3349 ||| NN
.  ||| S:3349 E:3351 ||| .
The  ||| S:3351 E:3355 ||| DT
ERG  ||| S:3355 E:3359 ||| NNP
base-case  ||| S:3359 E:3369 ||| JJ
estimate  ||| S:3369 E:3378 ||| NN
of  ||| S:3378 E:3381 ||| IN
the  ||| S:3381 E:3385 ||| DT
cost  ||| S:3385 E:3390 ||| NN
per  ||| S:3390 E:3394 ||| IN
QALY  ||| S:3394 E:3399 ||| NNP
of  ||| S:3399 E:3402 ||| IN
trabectedin  ||| S:3402 E:3414 ||| NN
in  ||| S:3414 E:3417 ||| IN
combination  ||| S:3417 E:3429 ||| NN
with  ||| S:3429 E:3434 ||| IN
PLDH  ||| S:3434 E:3439 ||| NNP
ranged  ||| S:3439 E:3446 ||| VBD
from  ||| S:3446 E:3451 ||| IN
£46,503  ||| S:3451 E:3459 ||| CD
to  ||| S:3459 E:3462 ||| TO
£54,607  ||| S:3462 E:3470 ||| CD
in  ||| S:3470 E:3473 ||| IN
the  ||| S:3473 E:3477 ||| DT
partially  ||| S:3477 E:3487 ||| RB
platinum-sensitive  ||| S:3487 E:3506 ||| JJ
population ||| S:3506 E:3516 ||| NN
.  ||| S:3516 E:3518 ||| .
At  ||| S:3518 E:3521 ||| IN
the  ||| S:3521 E:3525 ||| DT
time  ||| S:3525 E:3530 ||| NN
of  ||| S:3530 E:3533 ||| IN
writing ||| S:3533 E:3540 ||| NN
,  ||| S:3540 E:3542 ||| ,
trabectedin  ||| S:3542 E:3554 ||| VBG
in  ||| S:3554 E:3557 ||| IN
combination  ||| S:3557 E:3569 ||| NN
with  ||| S:3569 E:3574 ||| IN
PLDH  ||| S:3574 E:3579 ||| NNP
for  ||| S:3579 E:3583 ||| IN
the  ||| S:3583 E:3587 ||| DT
treatment  ||| S:3587 E:3597 ||| NN
of  ||| S:3597 E:3600 ||| IN
women  ||| S:3600 E:3606 ||| NNS
with  ||| S:3606 E:3611 ||| IN
relapsed  ||| S:3611 E:3620 ||| JJ
platinum-sensitive  ||| S:3620 E:3639 ||| JJ
ovarian  ||| S:3639 E:3647 ||| JJ
cancer  ||| S:3647 E:3654 ||| NN
is  ||| S:3654 E:3657 ||| VBZ
not  ||| S:3657 E:3661 ||| RB
recommended  ||| S:3661 E:3673 ||| VBN
by  ||| S:3673 E:3676 ||| IN
NICE  ||| S:3676 E:3681 ||| NNP
in  ||| S:3681 E:3684 ||| IN
the  ||| S:3684 E:3688 ||| DT
final  ||| S:3688 E:3694 ||| JJ
appraisal  ||| S:3694 E:3704 ||| NN
determination ||| S:3704 E:3717 ||| NN
.  ||| S:3717 E:3719 ||| .
